Science World

Pfizer’s new coronavirus treatment cuts hospitalisation by 89 per cent, trial results indicate

FILE PHOTO - A woman holds a small bottle labeled with a Coronavirus COVID-19 Vaccine sticker and a medical syringe in front of the displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS-Dado Ruvic

Pfizer’s new experimental COVID-19 anti-viral treatment cuts the risk of hospitalisation by 89%, the company has announced.

The results appear to surpass those seen with Merck & Co Inc’s pill Molnupiravir, which was shown last month to halve the likelihood of dying or needing hospital treatment for COVID-19.

Full trial data is not yet available from either company.

Pfizer plans to submit the interim trial results to the US Food and Drug Administration as part of an emergency use application.

It will ask international regulators to authorise the pill as soon as possible and a decision could be made by the FDA within weeks or months.

The results came from a study of 775 adults. Patients taking the company’s drug, along with another antiviral, had an 89% reduction in their combined rate of hospital admission or death after a month, compared to patients taking a placebo.

Get more stories like this on Twitter and Telegram

Recommended Stories